Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
25 hedge funds and large institutions have $7.83M invested in Evoke Pharma in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 10 closing their positions.
893% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $155K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
16% more capital invested
Capital invested by funds: $6.75M → $7.83M (+$1.08M)
0.02% more ownership
Funds ownership: 0.07% → 0.09% (+0.02%)
17% less funds holding
Funds holding: 30 → 25 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.98M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$935K |
| 3 |
Morgan Stanley
New York
|
+$611K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$299K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$83.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$483K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$208K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$168K |
| 4 |
Two Sigma Advisers
New York
|
-$86.4K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$208K | -520 | Closed |
|
|
SM
27
Sabby Management
Miami Beach,
Florida
| – | -$168K | -451 | Closed |
|
|
CAN
28
Cetera Advisor Networks
El Segundo,
California
| – | -$78K | -210 | Closed |
|
29
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$77K | -209 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | -$69.2K | -173 | -99% |
|
31
Goldman Sachs
New York
| – | -$54K | -146 | Closed |
|
|
VF
32
Virtu Financial
New York
| – | -$47K | -127 | Closed |
|
33
Charles Schwab
San Francisco,
California
| – | -$38K | -100 | Closed |
|
34
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3K | -8 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$3K | -8 | Closed |
|
EVOK Hedge Fund Activity: Q1 2021 in Review
25 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2021, worth a combined $7.83M — up 16% from $6.75M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of EVOK and 5 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.98M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $483K sold.
- 25 institutional investors held Evoke Pharma (EVOK) as of Q1 2021, down from 30 in Q4 2020.
- Funds reported $7.83M of Evoke Pharma stock for Q1 2021, up 16% quarter-over-quarter.
- 5 funds opened new Evoke Pharma positions in Q1 2021 and 10 closed out, a net change of -5 holders.
- The largest Evoke Pharma buyer in Q1 2021 was AIGH Capital Management, an estimated $3.98M added.
- The largest Evoke Pharma seller in Q1 2021 was Renaissance Technologies, an estimated $483K sold.
Based on aggregated 13F filings for Q1 2021.